UNITED KINGDOM – AstraZeneca has announced that it would pay Ionis Pharmaceuticals, the market leader in RNA-targeted therapies, US$200 million for the rights to its investigational medicine, eplontersen. Eplontersen is…
Read MoreTag: Alexion Pharmaceuticals
AstraZeneca completes its US$39B buyout deal of Alexion as it sets to expand its portfolio into rare diseases
UK – AstraZeneca has completed its buyout process of Alexion pharmaceuticals in a move that will see the British pharma giant venture extensively into immunology medicines and rare disease therapy.…
Read MoreAstraZeneca’s acquisition of Alexion near completion following clearance from European Commission
UK – AstraZeneca, a British-Swedish multinational pharmaceutical and biotechnology company, is finally on course to secure Alexion, a pharma company that specializes in rare disease, following a go-ahead approval from…
Read More